Liraglutide trial targeting epicardial fat and monoclonal gammopathies withdrawn before enrollment

Monoclonal gammopathies, including Monoclonal Gammopathy of Undetermined Significance (MGUS), are characterized by the proliferation of a single clone of plasma cells producing a monoclonal immunoglobulin. While often asymptomatic, MGUS can progress to more serious conditions like multiple myeloma. Emerging research suggests a link between obesity, epicardial fat accumulation, and the progression of these gammopathies, potentially through altered lipid metabolism and inflammation. Current management primarily focuses on monitoring or treating advanced stages, leaving a gap for early intervention strategies that address metabolic risk factors. Targeting epicardial fat and its lipid content with agents like GLP-1RAs could offer a novel approach to modulate disease progression.

This Phase 4 clinical trial (NCT02920190) was designed to investigate the effect of Liraglutide on monoclonal gammopathies in overweight/obese participants. The intervention involved administering Liraglutide 1.8 mg subcutaneously once daily for 12 consecutive months. Eligible participants were to have a BMI ≥27 kg/m2 and at least one overweight/obesity-related comorbidity (e.g., type 2 diabetes, hypertension, dyslipidemia). The primary endpoint was the change in epicardial fat thickness, measured in mm via ultrasound, from baseline to 12 months. Secondary outcomes included changes in serum immunoglobulins and plasma ceramide levels.

This Phase 4 clinical trial (NCT02920190) was officially withdrawn on 2021-12-31, prior to enrolling any participants. The stated actual enrollment was 0. Consequently, no empirical data regarding the effects of Liraglutide on primary or secondary endpoints were collected or reported. The study's objectives, which included assessing changes in epicardial fat thickness, serum immunoglobulins, and plasma ceramide levels, therefore remain unaddressed by empirical findings from this specific trial. No statistical analyses, p-values, or effect sizes can be derived from this withdrawn study. The intended investigation into Liraglutide's potential to reduce antigen-lipid-driven monoclonal gammopathies by targeting epicardial fat and its lipid content did not yield any results for evaluation. The trial's withdrawal means that the hypothesis, while intriguing, lacks direct evidence from this particular study.